Zurita, A. J.Diestra, J. E.Condom i Mundó, EnricGarcía del Muro Solans, XavierScheffer, G. L.Scheper, R. J.Pérez, J.Germà Lluch, José RamónIzquierdo, M. A.2018-03-132018-03-132003-03-240007-0920https://hdl.handle.net/2445/120651This study was undertaken to investigate the expression and predictive value for outcome of multidrug resistance-associated (MDR) proteins P-glycoprotein (Pgp), MRP1, BCRP, and LRP, in advanced testicular germ-cell tumours (TGCT). Paraffin-embedded sections from 56 previously untreated patients with metastatic TGCT were immunostained for Pgp, MRP1, BCRP, and LRP. All patients received platinum-based chemotherapy after orchidectomy. Immunostaining was related to clinicopathological parameters, response to chemotherapy, and outcome. Strong and intermediate expressions of the different MDR-related proteins were: 27 and 41% (Pgp), 54 and 37% (MRP1), 86 and 7% (BCRP), and 14 and 29% (LRP). P-glycoprotein and MRP1 associated, respectively, to low AFP (P=0.026) and high LDH levels (P=0.014), whereas LRP expression associated with high β-hCG levels (P=0.003) and stage IV tumours (P=0.029). No correlation was found between Pgp, MRP1, and BCRP expression and response to chemotherapy and survival. In contrast, patients with LRP-positive tumours (strong or intermediate expression) had shorter progression-free (P=0.0006) and overall survival (P=0.0116) than LRP-negative patients, even after individual log-rank adjustments by statistically associated variables. Our data suggest that a positive LRP immunostaining at the time of diagnosis in metastatic TGCT is associated with an adverse clinical outcome.8 p.application/pdfengcc-by-nc-sa (c) Zurita, A. J. et al., 2003http://creativecommons.org/licenses/by-nc-sa/3.0/esMalalties del testicleCèl·lules germinalsTumorsExpressió gènicaProteïnes supressores de tumorsResistència als medicamentsTestis diseasesGerm cellsTumorsGene expressionTumor suppressor proteinDrug resistanceinfo:eu-repo/semantics/article5248762018-03-13info:eu-repo/semantics/openAccess12644825